海思科(002653.SZ)：获得创新药HSK39297片新适应症《药物临床试验批准通知书》

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of HSK39297 tablets, a new drug for treating generalized myasthenia gravis, which has independent intellectual property rights [1] Group 1 - The clinical trial approval was granted based on the review of the application submitted in August 2025 [1] - HSK39297 tablets are developed independently by the company [1] - The drug is specifically aimed at treating generalized myasthenia gravis [1]